Form 4: Lilly Endowment Sells $340M Eli Lilly Stock

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., sold 309,842 shares of common stock for approximately $340 million through pre-arranged transactions.

Summary

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co. (LLY), disposed of 309,842 shares of common stock.
• The transactions occurred on January 7, 2026.
• Shares were sold at weighted average prices ranging from $1,085.108 to $1,116.686 per share.
• The total value of the shares sold is approximately $340 million.
• Following these transactions, Lilly Endowment Inc. directly owns 91,896,978 shares of Eli Lilly & Co. common stock.
• The sales were conducted pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.

Sentiment

Score: 5

Explanation: The sale by a 10% owner is a routine disclosure for a pre-planned transaction (10b5-1 plan). While it's a large dollar amount, it represents a small fraction of the total holdings and doesn't necessarily signal a change in the company's fundamental outlook.

Positives

• The transactions were executed at high share prices, ranging from $1,085.00 to $1,117.11, indicating a favorable market for the sale.
• The sales were conducted under a Rule 10b5-1(c) plan, suggesting a pre-planned and orderly disposition of shares rather than a reaction to new, negative information.

Negatives

• A significant insider, a 10% owner, reduced its stake in the company, which could be interpreted by some investors as a lack of conviction, although it represents a small percentage of their total holding.

Future Outlook

na

Industry Context

na

Related Party Transactions

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., sold shares of the company's common stock. This constitutes a transaction by a related party.

Stakeholder Impact

• Shareholders: The sale by a significant institutional shareholder could be viewed with slight caution, though the 10b5-1 plan mitigates concerns about immediate negative sentiment. The volume is relatively small compared to the total outstanding shares.
• Company: No direct operational impact on Eli Lilly & Co. is indicated by this transaction.

Key Dates

Recommendation

The filing is a routine disclosure of a pre-planned insider sale by a 10% owner. It does not provide new fundamental information about Eli Lilly & Co.'s operations, financial health, or future prospects that would warrant a change in investment thesis. The sale is likely for portfolio rebalancing or philanthropic purposes, given the nature of the reporting entity, and was executed at strong prices. Therefore, a 'hold' recommendation is appropriate as there's no new information to alter an existing position.

Keywords

Eli Lilly & Co., LLY, Lilly Endowment Inc., Insider Sale, Form 4, Stock Transaction, 10b5-1 Plan, Pharmaceuticals, Biotechnology